Company news

Johnson & Johnson news in 2026

Johnson & Johnson's news releases, calls and decks from 2026, newest first.

View company

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

January 27, 2026

Resolve M Therapeutics exits from stealth

January 22, 2026

Johnson & Johnson reports Q4 and Full-Year 2025 results

January 21, 2026

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

January 14, 2026

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

January 13, 2026

Distalmotion Secures Strategic Investment to Advance ASC Expansion of the DEXTER® Robotic Surgery System

January 12, 2026

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

January 10, 2026

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

January 8, 2026

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

January 7, 2026

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

January 6, 2026

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

January 2, 2026

← Newer news releases

Calls in 2026

Decks in 2026